Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02268396 · ClinicalTrials.gov registry record · Phase 3
Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD
A Phase 3 study, sponsored by Pearl Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 138
- Enrollment target
NCT02268396 is a Phase 3 study that has completed, run by Pearl Therapeutics. The registered enrollment target is 138 participants.
The verdict
NCT02268396, a Phase 3 study, has completed, sponsored by Pearl Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 138 participants
- Enrollment target
Study Summary
This is an open-label, multi-center study to evaluate the accuracy, reliability and functionality of the Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) dose indicator in adult subjects with moderate to very severe COPD over a 4-week Treatment Period.
Interventions
- DRUG Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2014-11 |
| Est. Completion | 2015-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02268396
The ClinicalTrials.gov registry entry for NCT02268396 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pearl Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler is the first listed.
NCT02268396 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02268396 about?
NCT02268396 is a clinical study titled "Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD". This is an open-label, multi-center study to evaluate the accuracy, reliability and functionality of the Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) dose indicator in adult subjects with moderate to very severe COPD over a 4-week Treatment Period.
What is the current status of trial NCT02268396?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 138 participants. The study started on 2014-11. Estimated completion is 2015-05.
What interventions are being tested in trial NCT02268396?
The interventions under investigation include: Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler (DRUG).
Who is sponsoring clinical trial NCT02268396?
This trial is sponsored by Pearl Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.